SINOVAC BIOTECH LTD SVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
7.1
Altman Z″ — distress risk · safe
—
Dividend payout · n/a
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $386.0M | — | $262.0M | -$561.1M | $4.4B |
| 2024 | $361.4M | — | $220.7M | -$152.9M | $10.3B |
| 2023 | $470.2M | -$13.5M | $323.3M | -$17.5M | $11.6B |
| 2022 | $1.5B | $14.5M | $815.2M | -$1.1B | $12.2B |
| 2021 | $19.4B | $8.1B | $18.4B | $14.7B | $13.6B |
| 2020 | $510.6M | $110.4M | $443.4M | $351.8M | $1.1B |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.1 (safe)
- Working capital / assets 0.647
- Retained earnings / assets 0.33
- EBIT / assets -0.057
- Equity / liabilities 2.069
Source: SEC EDGAR filings · CIK 0001084201 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.